1 / 3

Ceritinib

Boc Sciences offers 1032900-25-6 Ceritinib in bulk, please inquire us to get a quote for 1032900-25-6 Ceritinib.<br>https://www.bocsci.com/ceritinib-cas-1032900-25-6-item-462148.html<br>

bocsci2018
Télécharger la présentation

Ceritinib

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Ceritinib - CAS 1032900-25-6 Catalog number: B0084- 462148 An anaplastic lymphoma kinase (ALK)-positive inhibitor used for the treatment of non- small cell lung cancer (NSCLC). It less potently inhibits IGF-1R, InsR, and STK22D and IC50 value is 8, 7, and 23 nM. LDK378 is also minimally effective against a panel of other kinases. In Sep 2016, Interim adverse events and efficacy data from phase III ASCEND-4 trial in non small cell lung cancer released by Novartis. In Oct 2016, efficacy data from the phase III ASCEND-3 and ASCEND-5 trial in non small cell lung cancer was presented. Please be kindly noted that our product can only be used for research to orgnizations or companies and we don't cooperate with personal buyers. Category Inhibitor Targets ALK SARS-CoV-2 Molecular Formula C28H36ClN5O3S Molecular Weight 558.14 Ordering Information Catalo g Numbe r Siz e Pric e Stoc k Quantity B0084- 462148 250 mg $298In stock 0 Bulk Inquiry Add to cart Chemical Information

  2. Category Inhibitor Molecular Formula C28H36ClN5O3S Molecular Weight 558.14 Specification Properties Reference Reading    Purity ≥98% Related CAS 1032900-25-6 (free base) 1380575-43-8 (2HCl) Appearance Solid Powder Synonyms 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)py rimidine-2,4-diamine, LDK-378, LDK378; LDK 378; Zykadia; NVP-LDK378-NX Solubility Soluble in DMSO. Storage Store at -20ºC Clinical Trial Information NCT Number Title Condition Or Disease Phase Start Date Sponsor Status NCT01283516A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase Tumors Characterized by Genetic Abnormalities of ALK Phase 1 January 2011 Novartis Pharmaceuticals Completed NCT01634763Study of Safety and Preliminary Efficacy for LDK378 in Japanese Tumors Characterized Phase 1 June Novartis Completed

  3. Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK) by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK) 2012 Pharmaceuticals NCT01685060LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib Non-Small Cell Lung Cancer Phase 2 November 26, 2012 Novartis Pharmaceuticals Completed NCT01685138LDK378 in Crizotinib na?ve Adult Patients With ALK-activated Non-small Cell Lung Cancer Non-Small Cell Lung Cancer Phase 2 March 13, 2008 Novartis Pharmaceuticals Completed NCT01742286Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) Anaplastic Lymphoma Kinase Phase 1 August 28, 2013 Novartis Pharmaceuticals Active, not recruiting Preparing Stock Solutions ConcentrationVolumeMass 1 mg 5 mg 10 mg 1 mM 1.7917 mL 8.9583 mL 17.9167 mL 5 mM 0.3583 mL 1.7917 mL 3.5833 mL 10 mM 0.1792 mL 0.8958 mL 1.7917 mL 50 mM - - - https://www.bocsci.com/ceritinib-cas-1032900-25-6-item-462148.html

More Related